Journal Information
Vol. 22. Issue S1.
Informe SESPAS 2008: Mejorando la efectividad de las intervenciones públicas sobre la salud
Pages 205-215 (April 2008)
Vol. 22. Issue S1.
Informe SESPAS 2008: Mejorando la efectividad de las intervenciones públicas sobre la salud
Pages 205-215 (April 2008)
Capítulo 4. Un sistema de salud integrado y centrado en los usuarios. Primum non nocere. Intervenciones sanitarias respetuosas con las preferencias de los individuos
Open Access
Los efectos negativos de las intervenciones preventivas basadas en el individuo. Informe SESPAS 2008
Negative effects of individual-based preventive interventions
Visits
1536
Soledad Márquez-Calderón
Corresponding author
soledadm.marquez@juntadeandalucia.es

Correspondencia: Soledad Márquez-Calderón. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía.
Agencia de Evaluación de Tecnologías Sanitarias de Andalucía, Sevilla, España
This item has received

Under a Creative Commons license
Article information
Abstract
Bibliography
Download PDF
Statistics
Resumen

Como se suele suponer que las intervenciones preventivas tienen pocos riesgos, la investigación sobre sus efectos negativos es escasa, tal como pone de manifiesto una revisión de la literatura médica española. Esos estudios analizan efectos a corto plazo (como falsos positivos de los cribados), pero no tratan efectos a largo plazo de las medidas poscribado (p. ej., fármacos preventivos) ni efectos negativos más intangibles (como la medicalización). Se produce una expansión acrítica de la medicina preventiva: continuas propuestas de nuevos cribados (incluidas las preenfermedades y los factores de riesgo) y vacunas. El balance entre beneficios y riesgos de esta expansión es, como mínimo, dudoso.

En este proceso la industria farmacéutica desempeña un papel clave, pero también hay que revisar cómo actúan otros agentes: profesionales y autoridades sanitarias, medios de comunicación y sociedad en general. Resaltamos sobre todo el papel de la profesión médica, pues sin ella no sería posible definir nuevas enfermedades y preenfermedades ni recomendar el uso de nuevas intervenciones preventivas.

La profesión médica tiene el prestigio suficiente ante el resto de los agentes para liderar cualquier cambio. Previamente las sociedades científicas deberían tener un debate interno sobre su papel actual en la adopción de nuevas intervenciones preventivas, sus relaciones con la industria y sus conflictos de interés. Algunas asociaciones médicas ya están adoptando un enfoque más crítico y analizando el impacto de sus propias recomendaciones preventivas sobre la medicalización de la vida.

Es necesario analizar de forma continuada los efectos adversos de las medidas preventivas implantadas en la práctica y establecer mecanismos para la evaluación crítica del balance beneficios-riesgos-costes de las nuevas intervenciones preventivas antes de incluirlas en la cartera de servicios. En la práctica clínica cotidiana habría que fomentar la participación de las personas en las decisiones y que los profesionales adopten el enfoque de la prevención cuaternaria.

Palabras clave:
Prevención primaria
Servicios preventivos
Cribado
Vacunas
Fármacos preventivos
Efectos adversos
Medicalización
Abstract

Because preventive interventions are usually assumed to carry few risks, research on their negative effects is scarce, as revealed by a review of the Spanish literature. The studies retrieved analyze short-term effects (such as false-positive results of screening tests), but do not evaluate the long-term effects of postscreening interventions (for example: preventive drugs) or even less tangible negative effects (such as medicalization). Uncritical spread of preventive medicine is occurring, with continual proposals for new screening tests (for pre-diseases and risk factors) and new vaccines. The risk-benefit ratio of this spread is, at the very least, doubtful.

The pharmaceutical industry plays a key role in this process but the role of other stakeholders (health professionals and health authorities, mass media and society) should also be reviewed. The present article highlights the role of the medical profession, since, without it, definition of new diseases and pre-diseases and the creation of guidelines on the use of new preventive interventions would not be possible.

The medical profession has sufficient prestige to lead any change. Before any change occurs, however, scientific societies should conduct an internal debate on their current role in the adoption of new preventive interventions, their relationships with the pharmaceutical industry and their conflicts of interest. Some medical associations are already adopting a more critical approach to the evaluation of the benefit-risk trade-off of new interventions and are analyzing the impact of their own preventive recommendations on the medicalization of life.

The adverse effects of the preventive measures implemented in health services should be continually assessed and procedures for the critical evaluation of the benefit-risk-cost trade-offs of new preventive interventions should be established before making decisions on their incorporation in the health services’ portfolio. Finally, in daily clinical practice, enhancing citizen participation in decisions and adopting the approach of quaternary prevention would be desirable.

Key words:
Primary prevention
Preventive health services
Mass screening
Vaccines
Preventive drugs
Adverse effects
Medicalization
Full text is only aviable in PDF
Bibliografía
[1.]
A.O. Berg, J.D. Allan.
Introducing the Third U.S. Preventive Services Task Force.
Am J Prev Med, 20 (2001), pp. 3-4
[2.]
US Preventive Services Task Force.
Guide to clinical preventive services: report of the US Preventive Services Task Force.
2nd ed., Williams & Wilkins, (1996),
[3.]
Agency for Healthcare Research and Quality [homepage on the internet]. Rockville: The Agency. Quality Guide to Clinical Preventive Services. US Preventive Services Task Force [citado 25 Jul 2007]. Disponible en: http://www.ahrq.gov/cli-nic/cps3dix.htm
[4.]
A. Segura-Benedicto.
Inducción sanitaria de los cribados: impacto y consecuencias. Aspectos éticos.
Gac Sanit, 20 (2006), pp. 88-95
[5.]
R. Moynihan.
Who pays for the pizza? Redefining the relationships between doctors and drug companies (II): disentanglement.
BMJ, 326 (2003), pp. 1193-1196
[6.]
R. Moynihan, A. Cassels.
Selling sickness: wow the world's biggest pharmaceutical companies are turning us all into patients.
Greystone Books, (2005),
[7.]
M. Angell.
The truth about the drug companies: how they deceive us and what to do about it.
Random House, (2004),
[8.]
R. Moynihan, I. Health, D. Henry.
Selling sickness: the pharmaceutical industry and disease mongering.
BMJ, 324 (2002), pp. 886-890
[9.]
D.L. Sackett.
The arrogance of preventive medicine.
CMAJ, 167 (2002), pp. 363-364
[10.]
R. Smith.
The trouble with medical journals.
Royal Society of Medicine Ltd, (2006),
[11.]
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
JAMA, 285 (2001), pp. 2486-2497
[12.]
S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr, L.T. Clark, D.B. Hunninghake, National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association, et al.
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Circulation, 110 (2004), pp. 227-239
[13.]
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
Diabetes Care, 20 (1997), pp. 1183-1197
[14.]
American Diabetes Association.
Position Statement. Diagnosis and classification of diabetes mellitus.
Diabetes Care, 27 (2004), pp. 5-10
[15.]
A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo, The National High Blood Pressure Education Program Coordinating Committee, et al.
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report.
JAMA, 289 (2003), pp. 2560-2572
[16.]
Saul S. Unease on industry's role in hypertension debate. The New York Times Online [internet]. 2006 May 20 [citado 28 Jun 2007]. Disponible en: http://www.nytimes.com/2006/05/20/bu-siness/20hyper.html?ex=1185768000&en=bd2ba66084b9238c&ei=5070
[17.]
Center for Science in the Public Interest [homepage on the Internet]. Washington: The Center [updated 2004 Sept 23]. CSPI Newsroom [citado 6 Ago 2007]. Disponible en: http://www.cspinet.org/integrity/press/200409231.html
[18.]
A. Monroy-Morcillo, S. Márquez-Calderón, T. Molina-López, J.C. Domínguez-Camacho, C. Bermúdez-Tamayo, A. Escolar-Pujolar.
Tendencias en la prescripción de fármacos preventivos en el distrito de atención primaria de Sevilla (2000-2003).
Gac Sanit, 19 (2005), pp. 471-474
[19.]
B. Als-Nielsen, W. Chen, C. Gluud, L.L. Kjaergard.
Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?.
JAMA, 290 (2003), pp. 921-928
[20.]
L.M. Schwartz, S. Woloshin, F.J. Fowler Jr, H.G. Welch.
Enthusiasm for cancer screening in the United States.
JAMA, 291 (2004), pp. 71-78
[21.]
US Food and Drug Administration. Center for Devices and Radiological Health [homepage on the Internet]. Whole body scanning. Using computed tomography (CT). Rockville: updated October 12, 2005 [citado 30 Jul 2007]. Disponible en: http://www.fda.gov/cdrh/ct
[22.]
M.P. Petticrew, A.J. Sowden, D. Lister-Sharp.
False-negative results in screening programs. Medical, psychological, and other implications.
Int J Techn Assess Health Care, 17 (2001), pp. 164-170
[23.]
P.B. Bach, J.R. Jett, U. Pastorino, M.S. Tockman, S.J. Swensen, C.B. Begg.
Computed tomography screening and lung cancer outcomes.
JAMA, 297 (2007), pp. 953-961
[24.]
J.P. Ioannidis, S.J. Evans, P.C. Gøtzsche, R.T. O’Neill, D.G. Almant, K. Schulz, CONSORT Group, et al.
Better reporting of harms in randomized trials: an extension of the CONSORT statement.
Ann Intern Med, 141 (2004), pp. 781-788
[25.]
M.R. Law, N.J. Wald, A.R. Rudnicka.
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.
BMJ, 326 (2003), pp. 1423-1429
[26.]
University of California San Diego [homepage on the Internet]. Statins Effects Study. San Diego: updated February 15, 2007 [citado 20 Jun 2007]. Disponible en: http://medicine.ucsd.edu/ses
[27.]
The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators.
Effect of rosiglitazone on the frequency of diabetes in patients with impaired fasting glucose: a randomized controlled trial.
Lancet, 368 (2006), pp. 1096-1105
[28.]
The DREAM Trial Investigators.
Effect of ramipril on the incidence of diabetes.
N Engl J Med, 355 (2006), pp. 1551-1562
[29.]
S.E. Nissen, K. Wolski.
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
N Engl J Med, 356 (2007), pp. 2457-2471
[30.]
Writing Group for the Women's Health Initiative Investigators.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial.
JAMA, 288 (2002), pp. 321-333
[31.]
F. Grodstein, T.B. Clarkson, J.E. Manson.
Understanding the divergent data on postmenopausal hormone therapy.
N Engl J Med, 348 (2003), pp. 645-650
[32.]
J.E. Rossouw, R.L. Prentice, J.E. Manson, L. Wu, D. Barad, V.M. Barnabei, et al.
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.
JAMA, 297 (2007), pp. 1465-1477
[33.]
Asociación Española para el Estudio de la Menopausia [Internet] [citado 4 Ago 2007]. Disponible en: http://www.aeem.es
[34.]
S. Márquez, R. Meneu.
La medicalización de la vida y sus protagonistas.
Gest Clin Sanit, 5 (2003), pp. 47-53
[35.]
A. Sen.
Health: perception versus observation.
BMJ, 324 (2002), pp. 860-861
[36.]
P.N. Trewby, A.V. Reddy, C.S. Trewby, V.J. Ashton, G. Brennan, J. Inglis.
Are preventive drugs preventive enough? A study of patients’ expectation of benefit from preventive drugs.
Clin Med, 2 (2002), pp. 527-533
[37.]
J. Gérvas, M. Pérez.
Uso y abuso del poder médico para definir enfermedad y factor de riesgo, en relación con la prevención cuaternaria.
Gac Sanit, 20 (2006), pp. 66-71
[38.]
J. Gérvas.
Moderación en la actividad médica preventiva y curativa. Cuatro ejemplos de necesidad de prevención cuaternaria en España.
Gac Sanit, 20 (2006), pp. 127-134
[39.]
E. Bailón, I. Del Cura, B. Gutiérrez, J. Landa, A. López, A. Blasco.
El consenso que no pudo ser.
Aten Primaria, 30 (2002), pp. 341-342
[40.]
Sociedad Española de Medicina Familiar y Comunitaria. La semFYC considera precipitada la decisión de incluir la vacuna del Virus del Papiloma Humano (VPH) en el calendario vacunal. Noticias semFYC. 2007;34 [revista en Internet] [publicada en octubre de 2007] [citado 7 Dic 2007]. Disponible en: http://server1.semfyc.es/es/noticias/NOTICIA-Semfyc/octubre307/opinionA.htm
[41.]
Sociedad Española de Salud Pública y Administración Sanitaria. Declaración de la Junta Directiva de SESPAS sobre la inclusión de una vacuna contra el virus del papiloma humano (VPH) en el calendario oficial [internet] [publicado el 12 de noviembre de 2007] [citado 9 Dic 2007]. Disponible en: http://www.sespas.es/fr_comun.html
[42.]
Fernández de Sanmamed MJ, Marquet R, Reguant M, Zapater F; Grup de Qualitat de la CAMFIC. Malalts de salut? Reflexions al voltant de les noves demandes i les respostes del sistema sanitari [internet]. Barcelona 2006 [citado 16 Dic 2007]. Disponible en: http://www.scmfic.org/grups_treball/al-tres/qualitat/Malalts_de_salut%20final.pdf
[43.]
J.J. Cohen, S. Cruess, C. Davidson.
40.1. Alliance between society and medicine. The public's stake in medical professionalism.
JAMA, 298 (2007), pp. 670-673
Copyright © 2008. Sociedad Española de Salud Pública y Administración Sanitaria
Download PDF
Idiomas
Gaceta Sanitaria
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?